Sphingolipids inhibit multistage carcinogenesis and protein kinase C.
Borek
C
C
New England Medical Center, Department of Radiation Oncology, Boston, Massachusetts 02111.
Merrill
A H
AH
D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D015197:Carcinogenicity Tests / Q000379:methods; D002460:Cell Line; D002471:Cell Transformation, Neoplastic / Q000187:drug effects*; D005720:Gamma Rays; D051379:Mice; D008809:Mice, Inbred C3H; D011493:Protein Kinase C / Q000037:antagonists & inhibitors*; D013107:Sphingolipids / Q000494:pharmacology*; D013110:Sphingosine / Q000031:analogs & derivatives / Q000494:pharmacology; D013755:Tetradecanoylphorbol Acetate / Q000633:toxicity
D016588:Anticarcinogenic Agents; D013107:Sphingolipids; D011493:Protein Kinase C; D013110:Sphingosine; D013755:Tetradecanoylphorbol Acetate; C005682:safingol